Barry Richard purchased $207K of FLNA (indirect holdings)

Barry Richard (President & CEO) purchased 440,206 indirectly-held shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.47 ($0.21M total) on 2026-11-16.

Original reporting
SEC EDGAR · Barry Richard
Published Nov 18, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FLNA
Bullish
medium confidence
Mentioned
$FLNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLNABullishLow
01

Why it matters

The disclosure provides a new, primary datapoint on CEO Barry Richard’s share accumulation, but it does not include any new company fundamentals, guidance, or regulatory/clinical catalyst.

02

Market read

Traders may monitor for follow-on insider activity, but the transaction size and lack of fundamental updates suggest limited immediate repricing risk.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article does not clarify whether the purchase was discretionary, part of compensation, or related to prior arrangements.

Relevance 5/10Novelty 6/10Timing: filed 2026-11-18, transaction dated 2026-11-16

Background

The article is an SEC Form 4 insider transaction disclosure for Filana Therapeutics, Inc. (FLNA).

Company-level read

Ticker impact

$FLNABullishMedium confidence
Context

SEC Form 4 shows FLNA CEO Barry Richard bought 440,206 shares at $0.4700 on 2026-11-16 via indirect holdings, totaling about $206.9K.

Expected impact

Likely limited near-term impact, with any reaction more sentiment-driven than fundamentals-driven.

Evidence & confidence

The filing is a primary Form 4 disclosure, but the dollar value is relatively small and there is no accompanying operational or guidance catalyst in the text.

Market effects

No sector read-through is provided beyond a single-company insider purchase.

None indicated.

None indicated.

Counterpoint

Insider buying in a Form 4 can reflect liquidity planning, diversification, or non-informational motives, especially with indirect holdings and no stated rationale.

Key entities

  • FLNA

    Filana Therapeutics, Inc., the Form 4 issuer.

  • Barry Richard

    President and CEO of FLNA, reporting an indirect open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FLNAMed

Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update – Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 prov

$FLNAMedAI 8/10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

$FLNAMed

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing